Boston, MA, United States of America

Nicole Hurst

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 120(Granted Patents)


Company Filing History:


Years Active: 2005-2011

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations by Inventor Nicole Hurst

Introduction

Nicole Hurst is a prominent inventor based in Boston, MA (US). She has made significant contributions to the field of immunoinflammatory disorders, holding a total of 6 patents. Her work focuses on developing methods and compositions that enhance treatment options for patients suffering from these conditions.

Latest Patents

Among her latest patents, one notable invention is titled "Methods and reagents for the treatment of immunoinflammatory disorders." This invention features a method for treating patients diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a tetra-substituted pyrimidopyrimidine, either alone or in combination with additional agents. Another significant patent is "Combinations for the treatment of immunoinflammatory disorders," which includes pharmaceutical compositions that combine dipyridamole and a corticosteroid.

Career Highlights

Throughout her career, Nicole has worked with various companies, including Combinatorx, Incorporated and Zalicus, Inc. Her innovative approaches have positioned her as a key figure in her field, contributing to advancements in medical treatments.

Collaborations

Nicole has collaborated with notable coworkers such as Palaniyandi Manivasakam and Edward Roydon Jost-Price. These partnerships have further enriched her research and development efforts.

Conclusion

Nicole Hurst's contributions to the field of immunoinflammatory disorders through her patents and collaborations highlight her role as an influential inventor. Her work continues to pave the way for new treatment methodologies that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…